McKesson spins off med-surg segment
McKesson Corporation announced its intention to separate its Medical-Surgical Solutions segment into an independent company (“NewCo”).
McKesson believes a separation will “further enhance the strategic opportunity and operational focus of both companies and unlock value for McKesson shareholders,” the company said. “The separation would advance McKesson and NewCo’s ability to create value for customers, partners, patients, and shareholders.”
McKesson will focus on opportunities that best align with its long-term enterprise strategies, advancing McKesson’s portfolio to focus investment on higher growth, higher margin opportunities in Oncology and Biopharma Solutions.
SMI welcomes new leadership: Lisa Hohman as Board Chair, Steve Mason and Amanda Chawla to Board of Directors
SMI® has appointed Lisa Hohman, CEO of Concordance as Board Chair; and Steve Mason, CEO, Global Medical Products and Distribution at Cardinal Health; and Amanda Chawla, Chief Supply Chain Officer and SVP for Stanford Medicine to its board of directors.
Hohman has been a member of SMI since 2010 and a board member since 2020. She said, “It is an honor to be board chair for an organization known for its commitment to the healthcare supply chain industry. I am committed to upholding SMI’s mission to make impactful and transformational change while serving the SMI community, alongside many of my peers and colleagues.”
“I look forward to collaborating with my fellow board members as we work together to understand and anticipate the evolving needs of our members and industry,” Mason said. “The mission of SMI is in deep alignment with our efforts at Cardinal Health and I appreciate the opportunity to contribute to the advancement of the healthcare supply chain in my new role on the board of directors.”
Since its inception in 2004, the SMI Board of Directors sets the strategy for SMI and the work of its members. The Board includes twelve members, 6 provider partners and 6 industry partners to ensure a balanced representation of its membership which consists of leaders from large integrated delivery networks (IDNs) as well as suppliers, manufacturers, distributors, technology, and service organizations.
Sports organization MotoAmerica first to use Abbott’s rapid blood test for concussion evaluation on-site at races
Abbott and MotoAmerica, the premier motorcycle road racing series in North America, announced that MotoAmerica is the first professional sports organization worldwide to use Abbott’s groundbreaking blood test to help assess suspected concussions for riders in the on-site medical facilities at all races.
Abbott’s test, the i-STAT TBI test cartridge, is used to evaluate patients 18 years of age and older who present with suspected mild traumatic brain injury (mTBI). It provides results in 15 minutes and may be used up to 24 hours after injury to help determine the need for a CT scan of the head. In 2024, Abbott’s i-STAT TBI test received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to quickly assess patients with suspected mTBI on the handheld i-STAT Alinityanalyzer at the patient’s side.